Viewing Study NCT06198751



Ignite Creation Date: 2024-05-06 @ 7:57 PM
Last Modification Date: 2024-10-26 @ 3:17 PM
Study NCT ID: NCT06198751
Status: RECRUITING
Last Update Posted: 2024-06-03
First Post: 2023-12-27

Brief Title: A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 HER2 Positive Breast Cancer
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co Ltd
Organization: Chia Tai Tianqing Pharmaceutical Group Co Ltd

Study Overview

Official Title: A Phase 2 Randomized Open-label Multicenter Study to Evaluate the Efficacy and Safety of TQB2102 for Injection for Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression
Status: RECRUITING
Status Verified Date: 2024-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To evaluate the efficacy and safety of neoadjuvant treatment with TQB2102 for injection in patients with Her2 positive breast cancer
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None